{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:25:30Z","timestamp":1784204730594,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vph.2025.107562","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:16:30Z","timestamp":1764692190000},"page":"107562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Nebivolol in the therapeutic landscape of heart failure: Mechanisms and clinical outcomes"],"prefix":"10.1016","volume":"162","author":[{"given":"Edoardo Roberto","family":"Ginghina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Fatima","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.vph.2025.107562_bb0005","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.vph.2025.107562_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"Authors\/Task Force Members","year":"2022","journal-title":"Eur. J. Heart Fail."},{"issue":"17","key":"10.1016\/j.vph.2025.107562_bb0015","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2025.107562_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116650","article-title":"Cardiovascular outcomes and molecular targets for the cardiac effects of sodium-glucose cotransporter 2 inhibitors: a systematic review","volume":"175","author":"Madonna","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tcm.2024.10.002","article-title":"Guidelines for treating heart failure","volume":"35","author":"Kittleson","year":"2025","journal-title":"Trends Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.vph.2025.107562_bb0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","volume":"12","author":"Beghini","year":"2025","journal-title":"ESC Heart Fail."},{"issue":"22","key":"10.1016\/j.vph.2025.107562_bb0035","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"9961","key":"10.1016\/j.vph.2025.107562_bb0040","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet Lond. Engl."},{"issue":"9496","key":"10.1016\/j.vph.2025.107562_bb0045","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet Lond. Engl."},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2025.107562_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/VHRM.S20669","article-title":"Nebivolol: impact on cardiac and endothelial function and clinical utility","volume":"8","author":"Toblli","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"issue":"9146","key":"10.1016\/j.vph.2025.107562_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet Lond. Engl."},{"issue":"9169","key":"10.1016\/j.vph.2025.107562_bb0065","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","journal-title":"Lancet Lond. Engl."},{"issue":"5","key":"10.1016\/j.vph.2025.107562_bb0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.101.5.558","article-title":"beta-adrenergic receptor blockade in chronic heart failure","volume":"101","author":"Bristow","year":"2000","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.vph.2025.107562_bb0075","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"10.1016\/j.vph.2025.107562_bb0080","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"19","key":"10.1016\/j.vph.2025.107562_bb0085","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2014.15241","article-title":"Association between use of \u03b2-blockers and outcomes in patients with heart failure and preserved ejection fraction","volume":"312","author":"Lund","year":"2014","journal-title":"JAMA"},{"issue":"7\u20138","key":"10.1016\/j.vph.2025.107562_bb0090","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1345\/aph.1G708","article-title":"Nebivolol: a third-generation beta-adrenergic blocker","volume":"40","author":"Veverka","year":"2006","journal-title":"Ann. Pharmacother."},{"issue":"8","key":"10.1016\/j.vph.2025.107562_bb0095","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5414\/CPP44344","article-title":"Nebivolol: a review of its clinical and pharmacological characteristics","volume":"44","author":"Gielen","year":"2006","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0100","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-3565(25)10549-1","article-title":"Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine\/NO-dependent mechanism","volume":"274","author":"Cockcroft","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.vph.2025.107562_bb0105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.CIR.102.6.677","article-title":"Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production","volume":"102","author":"Broeders","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.vph.2025.107562_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11530710-000000000-00000","article-title":"Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release","volume":"70","author":"Kamp","year":"2010","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.vph.2025.107562_bb0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/01.ATV.0000065234.70518.26","article-title":"Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells","volume":"23","author":"Mollnau","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.vph.2025.107562_bb0120","first-page":"677","article-title":"Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats","volume":"48","author":"Oelze","year":"2006","journal-title":"Hypertens. Dallas Tex 1979"},{"issue":"4","key":"10.1016\/j.vph.2025.107562_bb0125","first-page":"660","article-title":"The effects of nebivolol on apoptosis in a rat infarct model","volume":"72","author":"Mercanoglu","year":"2008","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/01.hjh.0000160216.86597.ff","article-title":"Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation","volume":"23","author":"Fratta Pasini","year":"2005","journal-title":"J. Hypertens."},{"issue":"24","key":"10.1016\/j.vph.2025.107562_bb0135","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1161\/CIRCULATIONAHA.105.556233","article-title":"Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans","volume":"112","author":"Mason","year":"2005","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.vph.2025.107562_bb0140","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (study of effects of Nebivolol intervention on outcomes and Rehospitalization in Seniors with heart failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.vph.2025.107562_bb0145","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","article-title":"Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial","volume":"11","author":"Cohen-Solal","year":"2009","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.vph.2025.107562_bb0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study","volume":"14","author":"Conraads","year":"2012","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0155","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ijcard.2013.01.277","article-title":"Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial","volume":"168","author":"Contini","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0160","article-title":"Management of patients with heart failure in clinical practice: differences between men and women","volume":"94","author":"Lenzen","year":"2008","journal-title":"Heart Br Card Soc."},{"issue":"5","key":"10.1016\/j.vph.2025.107562_bb0165","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","article-title":"The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment","volume":"24","author":"Komajda","year":"2003","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.vph.2025.107562_bb0170","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/vhrm.2006.2.3.303","article-title":"Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation","volume":"2","author":"Weiss","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"issue":"1","key":"10.1016\/j.vph.2025.107562_bb0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2008.172","article-title":"Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users","volume":"85","author":"Bijl","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1755-5922.2008.00054.x","article-title":"Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide","volume":"26","author":"Gupta","year":"2008","journal-title":"Cardiovasc. Ther."},{"issue":"3","key":"10.1016\/j.vph.2025.107562_bb0190","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00051145","article-title":"Exercise tolerance with nebivolol and atenolol","volume":"6","author":"Van Bortel","year":"1992","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"12","key":"10.1016\/j.vph.2025.107562_bb0195","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute working group summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.vph.2025.107562_bb0200","first-page":"140","article-title":"MicroRNAs in acute myocardial infarction: evident value as novel biomarkers?","volume":"19","author":"Chen","year":"2018","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.vph.2025.107562_bb0205","doi-asserted-by":"crossref","unstructured":"Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold standard--lessons from the history of RCTs. N. Engl. J. Med. 2016 June 2;374(22):2175\u20132181.","DOI":"10.1056\/NEJMms1604593"},{"issue":"23","key":"10.1016\/j.vph.2025.107562_bb0210","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.jacc.2018.03.521","article-title":"Artificial Intelligence in Cardiology","volume":"71","author":"Johnson","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"22","key":"10.1016\/j.vph.2025.107562_bb0215","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.vph.2025.107562_bb0220","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/jama.2018.14852","article-title":"Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial","volume":"320","author":"Borlaug","year":"2018","journal-title":"JAMA"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189125001028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189125001028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:16:59Z","timestamp":1781335019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189125001028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"alternative-id":["S1537189125001028"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2025.107562","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nebivolol in the therapeutic landscape of heart failure: Mechanisms and clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2025.107562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107562"}}